Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2026Translational Andrology and UrologyOpen Access

The evolving role of adjuvant immune checkpoint inhibitors in urothelial carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAdanma AyanambakkamABArnab BasuWinnMed

Discussion

Loading...

Member takes

Overview

Analysis shows improved outcomes with adjuvant immune checkpoint inhibitors in urothelial carcinoma, suggesting significant therapeutic potential.

Key Points

  • Immune checkpoint inhibitors improve overall survival in urothelial carcinoma patients.
  • Key evidence indicates a 40% reduction in disease recurrence with these therapies.
  • Assessment of tumor microenvironment and biomarkers guides the use of adjuvant therapy.
  • The findings highlight a need for further multi-center trials in diverse populations.

Cite This Study

Ayanambakkam et al. (2026) studied this question.

synapsesocial.com/papers/69a75aefc6e9836116a2167chttps://doi.org/10.21037/tau-2025-aw-749
View Full Paper
Ask AI
Bookmark
Share